Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diet & Nutrition
FDA review period extended for chromium picolinate diabetes-related petition
July 24th, 2005
The U.S. Food and Drug Administration (FDA) has requested a 60-day extension for the review of Nutrition 21, Inc.'s, (NXXI) qualified health claim petition associating chromium picolinate with a reduced risk of insulin resistance, type 2 diabetes, and related disease. The petition is based on a compilation of more than 50 scientific studies supporting its safety and efficacy, according to the company. The company has agreed to the request and is taking measures to facilitate a timely decision. There are a number of other qualified health claim petitions for other nutritional ingredients before the FDA that are experiencing similar delays. "The...
Source: Medical Letter on the CDC & FDA (2005-07-24)
|
